Stock Ratings / Health Care / ATNM / earnings

BMEA (30) MREO (37) ELTX (28) HOWL (42) ⌘ Pro Terminal →

Actinium Pharmaceuticals Inc. (Delaware) (ATNM) Next Earnings Date & Expected ±12.5% Move

$1.48 -3.27% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.47

Actinium Pharmaceuticals Inc. (Delaware) (ATNM) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $46.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ATNM Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ATNM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Actinium Pharmaceuticals Inc. (Delaware) (NYSE: ATNM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $1.48 (-3.27% 1D, market cap $46.5M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ATNM ranks #414 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ATNM compare to BMEA and MREO in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ATNM carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BMEA (Biomea Fusion Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $46.4M) and MREO (Mereo BioPharma Group plc) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $46.2M). Among the 5-stock peer group, ATNM leads on earnings multiple (N/A) while ATNM leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ATNM?

▼

Per ATNM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001388320), Actinium Pharmaceuticals Inc. (Delaware) generated $90.0K in revenue, -$33.9M in net income, and -$24.7M in free cash flow against $51.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.47 (-0.78%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (43/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-6.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-6.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ATNM)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (43/100 Composite)

🔍 WHY ATNM SCORES 43/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (33% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (23% of score)

FRED Regime × Technicals: 76% of 52W Range • RSI-14 at 59.7 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.00+40% Next Q

Q2 (-2Q)

Grade E$1.40+1.4% Next Q

Q3 (-1Q)

Grade D$1.42+4.2% Next Q

Current

Grade D-$1.48-6.7% Hist 90D α

Trajectory: E (35) → D- (43)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ATNM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ATNM currently carries a cautious 43/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.21) and Max Pain ($1.55) forces dealer call-delta covering toward $1.81.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ATNM• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ATNM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 43%NO 57%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.18 Expected Swing

MODEL EARNINGS SETUP GAUGE

ATNM Quantitative Pre-Earnings Setup: 43/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (43/100)Model Risk Weight (57/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$90.0K	-$33.9M	-$24.7M	52%
FY 2024	2024-12-31	$0	-$38.2M	-$33.1M	52%
FY 2023	2023-12-31	$81.0K	-$48.8M	-$47.3M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ATNM)

✓Walkthrough of ATNM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ATNM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +23.33%📐 HORIZONTAL RANGE

2026-11-03O $1.53H $1.53L $1.48C $1.48VOL 157.7K

RES: $1.73SUP: $0.94SMA50: $1.21SMA200: $1.12

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ATNM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ATNM Butterfly Map → + Track ATNM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ATNM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ATNM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ATNM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ATNM)

Health Care Rank #414 of 1016 ⚔️ BMEA vs ATNM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ATNM vs. BMEA, MREO, ELTX, HOWL)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Actinium Pharmaceuticals Inc. (Delaware) (ATNM) ranks #414 by composite RQD confidence (43/100, grade D-) and #756 by equity capitalization ($46.5M). Within this direct 5-issuer industry benchmark cohort, ATNM leads on earnings valuation at N/A trailing P/E, while ATNM leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ATNM currently leads its immediate peer cohort in composite quantitative strength at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ATNM ACTIVE Actinium Pharmaceuticals Inc. (Delaware)	D-	43/100	—	—	-35.0%	-3.27%	$46.5M	Benchmark Subject
BMEA Biomea Fusion Inc.	E	30/100	—	—	-35.0%	+2.68%	$46.4M	/bmea-vs-atnm →
MREO Mereo BioPharma Group plc	D-	37/100	—	—	-35.0%	-4.08%	$46.2M	/mreo-vs-atnm →
ELTX Elicio Therapeutics Inc.	E	28/100	—	—	-35.0%	-4.00%	$45.5M	/eltx-vs-atnm →
HOWL Werewolf Therapeutics Inc.	D-	42/100	—	—	-35.0%	-10.35%	$47.9M	/howl-vs-atnm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001388320

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Actinium Pharmaceuticals Inc. (Delaware) (ATNM) reported GAAP revenue of $90.0K (N/A vs. FY2024 revenue of $0 , and +11.1% cumulative change since FY2023) , GAAP net income of -$33.9M, operating cash flow of -$24.6M, and free cash flow of -$24.7M (+25.4% YoY). On the balance sheet, ATNM closed FY2025 with $51.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$90.0K	-$33.9M	-$24.6M	-$24.7M	$51.8M	—
FY2024 (FY)	2024-12-31	$0	-$38.2M	-$33.1M	-$33.1M	$76.9M	—
FY2023 (FY)	2023-12-31	$81.0K	-$48.8M	-$47.3M	-$47.3M	—	—

3. ATNM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ATNM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ATNM compare to BMEA and MREO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ATNM?

Where is ATNM trading relative to its 50-day, 200-day, and 52-week technical levels?

ATNM last traded at $1.48 (-3.27% on volume of 157,726 shares), positioning the stock +22.31% above its 50-day simple moving average ($1.21) and +32.14% above its 200-day simple moving average ($1.12). Across its 52-week range of $0.74 to $1.72, ATNM sits at the 75.5% percentile with a 14-day RSI of 59.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($1.30 to $1.66).

ATNM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is ATNM's next earnings date?

Based on SEC filing cadence, Actinium Pharmaceuticals Inc. (Delaware) (ATNM)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is ATNM stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for ATNM, spanning a range between $1.3 and $1.66.

Direct Sub-Reports: ATNM RQD Cockpit ATNM 12M Forecast ATNM Earnings & Move ATNM Dividends & DRIP ATNM Insiders & 13F ATNM Whale Options ATNM Profit Sankey ATNM News & Why

ROARABLE RATING BRIEF • RQD 43/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ATNM — Actinium Pharmaceuticals Inc. (Delaware): What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:47:02Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ATNM carries an RQD Score of 44 with a letter grade of D, labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 8/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 14/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 11/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 8/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5). The weakest pillar is Insider Conviction, and the two fundamentals-linked pillars (Cash Engine and Forensic Balance Sheet) each score 8/20. For a prospective investor, the rating implies that the sharpest weakness is in cash generation and insider signals, while the institutional-flow pillar is the relative bright spot. The fundamental pillars indicate that the company is not currently self-funding; upside, if any, would depend on factors outside the reported cash-engine metrics. Valuation cannot be anchored on earnings, because the P/E and EPS fields are not available in source data.

Business

Actinium Pharmaceuticals Inc. (Delaware) (ATNM) is a NYSE-listed issuer. Per the company profile, it operates in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. The source data does not identify its specific products, customers, or revenue model. Reported revenue appears in the SEC financials at $0.1M for FY 2025 and $0.0M for FY 2024, which indicates minimal commercial revenue in the periods provided.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.1M	$-36.2M	$-33.9M	N/A	$-24.7M	$48.0M	N/A
FY 2024	$0.0M	$-42.1M	$-38.2M	N/A	$-33.1M	$72.9M	N/A
FY 2023	$0.1M	$-51.9M	$-48.8M	N/A	$-47.3M	N/A	N/A

Per the SEC financials, operating and net losses narrowed from FY 2023 to FY 2025 while cash declined from $72.9M to $48.0M over FY 2024 to FY 2025. Per the market data, gross margin is 0%, operating margin is -60%, net margin is -60%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, with Debt/Equity at 0.5. The debt line is N/A in the SEC financials, so the balance-sheet reading relies on the rating's Debt/Equity figure rather than reported debt.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Sector classification is Health Care and industry is Biotechnology: Pharmaceutical Preparations. No upstream or downstream dependencies, sector correlations, or second-order bottlenecks are identified in source data.

Open Questions

What specific products or development programs generate the revenue reported in the SEC financials, and at what stage are they?
What are the reported debt figures, given that the debt field is N/A across all three periods while Debt/Equity is cited at 0.5?
What are the TTM EPS and earnings-based valuation multiples, which are not available in source data?
What is the current cash runway relative to the FY 2025 FCF of $-24.7M and cash of $48.0M?
What drove the 10.87% price change and the 52-week range move, given that no recent news or catalysts are provided?

ATNM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Actinium Pharmaceuticals Inc. (Delaware) (ATNM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ATNM Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo • 18h ago

Actinium Pharmaceuticals Announces Acceptance of ATNM-400 Abstract for Presentation at SABCS 2026 Highlighting Activity Across Therapy-Resistant Breast Cancer Models

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced that an abstract highl

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 3d ago

Actinium Pharmaceuticals Announces Inducement Grant to New Employee

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced an inducement equity award to a newly hired non-executive emplo

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 5d ago

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers Axogen (NASDAQ:AXGN) stock rose 17.7% to $44.1 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q3 earnings report came out today.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 10d ago

Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 10d ago

Actinium Pharma To Present First‑In‑Human Phase 1 Study Of ATNM‑400, HER3-Targeted, Non-PSMA Radiotherapy, In Metastatic Castration‑Resistant Prostate Cancer, At ESMO Congress 2026

First‑in‑human Phase 1 study evaluates HER3‑targeted ATNM‑400 in metastatic castration‑resistant prostate cancer population, including patients with and without prior PSMA‑directed therapy HER3‑targeted alpha

Read Full Source ↗

🟢 CATALYST Benzinga • 13d ago

Why Is Actinium Pharmaceuticals Stock Gaining Tuesday?

Actinium Pharmaceuticals shares jump 9% after positive Phase 1 ATNM-400 trial results in prostate cancer show early safety and retention.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 13d ago

Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 13d ago

Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ATNM Bull vs. Bear Conversation Board — What's Your Call at $1.48?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ATNM 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.35 (-11.8%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ATNM (D • RQD 44/100) a Buy at $1.53?

Welcome to the ATNM (Actinium Pharmaceuticals Inc. (Delaware)) Roar Pit. Current RQD Composite is 44/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.29 (-15.7%)

Spot @ $1.53

Pump the brakes on ATNM — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ATNM, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Actinium Pharmaceuticals Inc. (Delaware) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.90 (+24.2%)

Spot @ $1.53

ATNM cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ATNM, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.53 (52-wk range $0.74 - $1.72), any beat on forward guidance forces shorts and underweight funds to chase.